Table 4.
Session product characteristics’ effects on symptom relief when using inhaled, dried Cannabis flower and treating cannabinoid measurements as continuous variables
| Overall Sample | Agitation/irritability | Anxiety | Stress | |
|---|---|---|---|---|
| (1) | (2) | (3) | (4) | |
| THC (%/dry wt.) | − 0.020*** (0.006) | 0.006 (0.018) | − 0.024** (0.008) | − 0.021* (0.009) |
| CBD (%/dry wt.) | − 0.002 (0.009) | 0.012 (0.015) | − 0.001 (0.010) | − 0.001 (0.012) |
| C. indica | − 0.014 (0.104) | − 0.209 (0.215) | 0.033 (0.133) | 0.018 (0.169) |
| C. sativa | 0.215 (0.111) | 0.162 (0.209) | 0.222 (0.127) | 0.250 (0.166) |
| Pipe | 0.093 (0.256) | 0.499 (0.653) | − 0.385 (0.213) | 0.498 (0.409) |
| Vape | 0.135 (0.274) | 0.708 (0.664) | − 0.222 (0.268) | 0.492 (0.406) |
| Session length (min) | − 0.007*** (0.001) | − 0.005* (0.002) | − 0.007*** (0.001) | − 0.008*** (0.001) |
| Baseline symptom intensity | − 0.662*** (0.040) | − 0.694*** (0.071) | − 0.608*** (0.069) | − 0.669*** (0.052) |
| Constant | 0.281 (0.296) | − 0.801 (0.744) | 0.639 (0.379) | − 0.058 (0.437) |
| Number of sessions | 2306 | 422 | 998 | 886 |
| Number of users | 670 | 206 | 441 | 360 |
Each column represents a separate regression. The outcome is the difference between the lowest reported symptom level within 4 h of initiating the session and the starting symptom level. The first column reports results for the whole sample, while columns 2 to 4 distinguish between specific distress-related symptoms reported. C. indica and C. sativa are relative to hybrid strains, and pipe and vape are relative to joint. All regressions are estimated using a fixed effects model and control for session length and baseline symptom intensity. Standard errors, clustered at the individual user level, are shown in parentheses
***p < 0.001, **p < 0.01, *p < 0.05